Published in Clinical Trials Week, November 14th, 2005
This conclusion is based on new findings from the BENEFIT (Betaferon/Betaseron in newly emerging MS for initial treatment) study presented at the joint 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), Thessaloniki, Greece, by Ludwig Kappos, professor of neurology and clinical neuroimmunology at the University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.